New Data Reinforce One In Three Rheumatoid Arthritis (RA) Patients Achieve Clinical Remission With Tocilizumab

Exciting new data from the TOWARD study, at the American College of Rheumatology (ACR) Annual Scientific Meeting in Boston, show that around one in three patients achieved clinical remission in the tocilizumab (Actemra) group, as assessed using DAS28







At 24 weeks significantly more patients achieved a 20%, 50% and 70% (ACR20, ACR50 and ACR70) reduction of symptoms with Actemra plus DMARDs compared to the control group. The ACR20, ACR50 and ACR70 was achieved in 61%, 38% and 21%, respectively, of Actemra plus DMARDs patients versus 25%, 9% and 3%, respectively, in the placebo plus DMARDs arm. Disease remission was demonstrated in 30% of Actemra patients (DAS28